Prenetics Accelerates Health-Crypto Convergence Strategy with $48M Funding Round and Aggressive Bitcoin Accumulation Plan

Prenetics has successfully closed a heavily oversubscribed capital raise, securing approximately $48 million in gross proceeds through a public equity offering. The round values the company’s equity at $16.08 per share and includes a two-tier warrant structure with potential upside to $216 million in total proceeds if all warrants are exercised. This strategic infusion arrives as the company’s flagship supplement brand, IM8, continues its unprecedented market momentum.

IM8’s Record-Breaking Growth Trajectory

The health and longevity brand has achieved a remarkable milestone: $100 million in annual recurring revenue within just 11 months of commercial launch—a pace unmatched in the global supplements industry’s history. The company projects revenues between $160-200 million for full-year 2026, positioning IM8 toward multi-billion-dollar valuations. October 2025 monthly revenue is projected to exceed $8.6 million, translating to a $103 million annualized run rate.

Operational metrics underscore the brand’s market traction. Since its December 2024 launch, IM8 has delivered over 12 million servings across 420,000-plus customer transactions spanning 31 countries. Approximately 80% of new orders stem from subscription purchases, indicating strong customer retention. The recent debut of Daily Ultimate Longevity drove average order value from $110 to $145, reflecting sustained premium product demand.

Strategic Investor Coalition Signals Confidence

The capital raise attracted a sophisticated mix of institutional and individual investors, signaling broad conviction in Prenetics’ dual-growth thesis. Notable participants include major cryptocurrency platforms, digital asset specialists, AI-driven biotech innovators, and Asia’s most influential family offices and business leaders.

Key strategic partners include investment vehicles led by pioneering Bitcoin infrastructure experts, quantum-computing-enabled drug discovery firms, and multi-billion-dollar digital asset management groups. Celebrity and sports personalities deepened their stakes, with tennis’s world No. 1 and four-time Grand Slam champion among existing shareholders increasing exposure. Prominent Asia-based visionaries and family office leaders—including original IPO cornerstone investors—reinforced positions, reflecting sustained conviction in the company’s global vision.

Bitcoin Treasury as Competitive Moat

Following closing, Prenetics will hold approximately $100 million in cash and roughly 275 Bitcoin (valued at $31 million as of late October 2025), totaling $131 million in liquidity. The company has committed to daily 1 BTC purchases commencing August 1, 2025, establishing a disciplined accumulation strategy designed to build substantial digital asset holdings alongside core business growth.

This dual-engine approach—combining explosive supplement brand scaling with systematic Bitcoin accumulation—represents a novel positioning for a consumer health company. The strategy positions shareholders for potential upside across both traditional revenue growth and digital asset appreciation.

Financial Roadmap and Strategic Reshaping

Leadership has outlined an ambitious five-year vision: $1 billion in annual revenue paired with $1 billion in Bitcoin holdings. To concentrate resources on the IM8 opportunity, the company is conducting a strategic review of non-core business units with intent to divest, reallocating focus and expertise toward the supplement brand’s global expansion.

The offering closed on or around October 28, 2025, following customary closing procedures. Management emphasized that investor confidence validates the market’s receptiveness to health-crypto integration and the supplement industry’s structural growth narrative.